Synthesis of some NH-derivatives of ciprofloxacin as antibacterial and antifungal agents

Bangladesh Journal of Pharmacology

Volumn 6, Issue 1, 2011, Pages 8-13

  Rabbani, Mohammad Golam ^a   Islam, Md Rabiul ^a   Ahmad, Mesbahuddin ^b   Hossion, Abugafar M L ^c  

^a JAHANGIRNAGAR UNIVERSITY   (Bangladesh)

^b Gono University   (Bangladesh)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Antibacterial; Antifungal; Ciprofloxacin; Schotten baumann method

Indexed keywords

7 (4 N ACETYL PIPERAZIN 1 YL) 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDRO QUINOLINE 3 CARBOXYLIC ACID; 7 (4 N BENZOYL PIPERAZIN 1 YL) 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDRO QUINOLINE 3 CARBOXYLIC ACID; 7 [4 (4 NITRO BENZOLYL) PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDRO QUINOLINE 3 CARBOXYLIC ACID; 7 [4 [3 (2 CHLORO 6 FLUORO PHENYL) 5 METHYL ISOOXAZOLE 4 CARBONYL] PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDRO QUINOLINE 3 CARBOXYLIC ACID; 7 [4 [3 (2 CHLORO PHENYL) 5 METHYL ISOOXAZOLE 4 CARBONYL] PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDRO QUINOLINE 3 CARBOXYLIC ACID; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BACILLUS; CANDIDA ALBICANS; COLONY FORMING UNIT; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SALMONELLA; SALMONELLA DYSENTERIAE; SALMONELLA TYPHI; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 84863757329     PISSN: 1991007X     EISSN: 19910088     Source Type: Journal    
DOI: 10.3329/bjp.v6i1.7720     Document Type: Article

References (12)

1. Bennish ML, Salam MA, Khan WA, Khan AM. Treatment of shigellosis: III. Comparison of one-or-two-dose ciprofloxacin with standard 5 day therapy: A randomized, blinded trial. Ann Intern Med. 1992; 117: 727-34.
2. Crumplin GC, Smith JT. Nalidixic acid bacterial chromosome replication. Nature 1976; 260: 643-45
3. de Souza NJ, Gupte SV, Deshpande PK, Desai VN, Bhawsar SB, Yeole RD, Shukla MC, Strahilevitz J, Hooper DC, Bozdogan B, Appelbaum PC, Jacobs MR, Shetty N, Patel MV, Jha R, Khorakiwala HF. A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. J Med Chem. 2005; 48: 5232-42.
4. Devnath HP, Islam MR. Synthesis of some pyrazolone derivatives from ciprofloxacin and study of their cytotoxicity. Bangladesh J Pharmacol. 2010; 5: 30-33.
5. Goots TD, Brighty KE. Fluoroquinolone antibacterials: SAR, mechanism of action, resistance and clinical aspects. Med Res Rev. 1996; 16: 433-86.
6. Hooper DC, Wolfson JS. Fluoroquinolone antibacterial agents. N Engl J Med. 1991; 324: 384-94.
7. Jubie S, Sikdar P, Kalirajan R, Gowramma B, Gomaathy S, Sankar S, Elanga K. Synthesis and antimicrobial activity of some novel ciprofloxacin analogues. J Pharma Res. 2010; 3: 511-13.
8. Ludlam HA, Barton I, White L, McMullin C, King A, Phillips I. Intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD). J Antimicrob Chemother. 1990; 25: 843-51.
9. Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding. DN. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med. 1989; 86: 801-08.
10. Siddiqui R, Sultana N, Khan KM, Akbar N, Ali M, Arayne S. Effects of skeletal modifications of ciprofloxacin on antibacterial, antifungal and cytotoxic activities. J Chinese Clin Med. 2007; 21: 188-95.
11. Wang JC. DNA topoisomerases. Annu Rev Biochem. 1985; 54: 665-97.
12. Yamashita Y, Ashizawa T, Morimoto M, Hosomi J, Nakano H. Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res. 1992; 52: 2818-22.